natgillin/translations-raw huggingface dataset:
<Manufacturer responsible for batch release:> 
<Nositelj odobrenja za Proizvođačdnju odgovoran za puštanje serije u promet:>
<The veterinary medicinal product should not be administered by pregnant women.> 
<Trudnice ne bi trebale primjenjivati veterinarsko-medicinski proizvod.>
<None known.> <No data available.> 
<Podaci nisu dostupni.>
<Vaccinated {species} may excrete the vaccine strain up to {x <days><weeks>} following vaccination.> 
<Cijepljene {vrste životinja} mogu izlučivati cjepni soj i do {x <dana><tjedana>} nakon cijepljenja.
<Consideration should be given to official guidance on the incorporation of medicated premixes in final feeds.> 
<Trebalo bi razmotriti, stavljanje ljekovitih premiksa u gotovu hranu za životinje, u službenim vodičima.>
<Shelf life of the veterinary medicinal product as packaged for sale: > <Shelf life after first opening the immediate packaging: > <Shelf life after <dilution><reconstitution> according to directions: > <Shelf life after incorporation into meal or pelleted feed: > 
<Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju: > <Rok valjanosti poslije prvog otvaranja unutarnjeg pakovanja: > <Rok valjanosti poslije <razrjeđenja><rekonstitucije> prema uputi: >
<Not authorised for use in animals producing milk for human consumption.> <Do not use in pregnant animals which are intended to produce milk for human consumption within {X} months of expected parturition.> <Not authorised for use in birds producing eggs for human consumption, including replacement chicks which are intended to produce eggs for human consumption.> <Not for use in birds producing or intended to produce eggs for human consumption.> 
<Ne primjenjivati na gravidnim životinjama koje su namijenjene za proizvodnju mlijeka za ljudsku upotrebu u roku od {X} mjeseci od očekivanog poroda.>
STATEMENT OF THE MRLs <D. 
IZVJEŠĆE O MRL
<Safety <and> <efficacy> data are available which demonstrate that this <vaccine><immunological veterinary medicinal product> can be mixed and administered with {description of tested product(s). 
<Dostupni podaci o <neškodljivosti> <i> <djelotvornosti> su dostupni i pokazuju da se ovo(aj) <cjepivo><imunološki veterinarsko-medicinski proizvod> može primijeniti pomiješan(o) s {opis ispitanog(nih) proizvoda.}>
<Medicines should not be disposed of via wastewater or <household waste>.> <Ask your <veterinary surgeon> <or> <pharmacist> how to dispose of medicines no longer required. 
<Pitajte vašeg <veterinara><farmaceuta> kako odlagati veterinarsko-medicinske proizvode lijekove koji vam više nisu potrebni.
<The excipients (including adjuvants) listed in section 6.1 of the SPC are <either> <allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required> <or> <considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product>.> 
<Pomoćne tvari (uključujući adjuvanse), navedene u dijelu 6.1 SPC su <ili> <dozvoljene tvari za koje je u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010 navedeno da određivanje MRL nije nužno>, <ili> <se smatra da se na njih ne primjenjuju odredbe Uredbe (EK) br. 470/2009 kada se primjenjuju u tim veterinarsko medicinskim proizvodima>.>
MANUFACTURER<S> RESPONSIBLE FOR BATCH RELEASE <Name and address of the manufacturer
 of the biological active substance
 {Name and address}> 
<Naziv i adresa proizvođača biološki djelatne<ih> tvari
<Pregnancy:> <and lactation:> 
<Graviditet:><i laktacija:> <Može se primijeniti tijekom graviditeta.>
<The excipients listed in section 6.1 of the SPC are <either> <allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required> <or> <considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product>.> 
<Pomoćne tvari navedene u dijelu 6.1 SPC su <ili> <dozvoljene tvari za koje je u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010 navedeno da određivanje MRL nije nužno> <ili> <se smatra da se na njih ne primjenjuju odredbe Uredbe (EK) br. 470/2009 kada se primjenjuju u tim veterinarsko medicinskim proizvodima.>>
Name and address of the manufacturer
 responsible for batch release {Name and address} <The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.> 
<Tiskana uputa o VMP mora sadržavati naziv i adresu proizvođača odgovornog za puštanje odnosne serije u promet.>
6.2 Major Iincompatibilities 
6.3 Rok valjanosti
4.4 Special warnings for each target species 
4.2 Indikacije za primjenu, navesti ciljne vrste životinja
<Veterinary medicinal product subject to prescription.> <Veterinary medicinal product not subject to prescription.> 
<Veterinarsko-medicinski proizvod se izdaje bez veterinarskog recepta.>
<Can be used during pregnancy.> <The use is not recommended (during the whole or part of the pregnancy).> <Do not use (during the whole or part of the pregnancy).> <The use is not recommended during <pregnancy><lactation>.> <Use only accordingly to the benefit-risk assessment by the responsible veterinarian.> <Laboratory studies in {species} have not produced any evidence of <teratogenic>, <foetotoxic>, <maternotoxic> effects.> <Laboratory studies in {species} have shown evidence of <teratogenic>, <foetotoxic>, <maternotoxic> effects.> 
<Potrebno je primijeniti primjerene veterinarske i stočarske mjere da bi se izbjeglo širenje cjepnog soja na primljive vrste životinja.> <{Vrste životinja} i ne cijepljene {vrste životinja} u kontaktu s cijepljenim {vrstama životinja} mogu reagirati na cjepni soj i pokazivati kliničke znakove kao što su …> Posebne mjere opreza koje mora poduzeti osoba koja primjenjuje veterinarsko-medicinski proizvod na životinjama <Nije primjenjivo.> <U slučaju da se nehotice <samo primjeni><samo injiciranja><proguta><prolije na kožu>, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.>
STATEMENT OF THE MRLs <Not applicable.> [For pharmaceutical products] The active substance
 in {name of the product} <is><are> <an> allowed substance
 as described in table 1 of the annex to Commission Regulation (EU) No 37/2010: Pharmaco-logically active substance 
Djelatna(e) tvar(i) u {naziv proizvoda} <je><su> dozvoljena<e> tvar<i> kako je navedeno u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010:
<The long-term effects of the veterinary medicinal product on the population dynamics of dung beetles have not been investigated. 
<Produženo djelovanje veterinarsko-medicinskog proizvoda na dinamiku populacije kotrljana još nije istraženo, stoga savjetujemo da ga ne primjenjujte na životinjama, na istoj paši svake sezone.>
<Not applicable.> <In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.> <Do not mix with any other veterinary medicinal product<, except <diluentsolvent or other component> <recommended><supplied> <for use with the veterinary medicinal product>.> 
<Ne miješati s bilo kojim drugim veterinarsko-medicinskim proizvodom<, osim <otapaldiluentom ili drugim komponentama>
EXPIRY DATE [For terms on Batch number and Expiry date see Appendix IV on the European Medicines Agency website http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/201 4/08/WC500170559.pdf] http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/20 09/10/WC500004426.pdf] 
ROK VALJANOSTI [For terms on Batch number and Expiry date see Appendix IV on the European Medicines Agency website http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/20 09/10/WC500004426.pdf]
<Safety> <and> <efficacy> data are available which demonstrate that this <vaccine><immunological veterinary medicinal product> can be administered at least {X} <days><weeks> <before><after> the administration of {description of tested product(s). 
<Dostupni podaci o <neškodljivosti> <i> <djelotvornosti> su dostupni i pokazuju da se ovo(aj) <cjepivo><imunološki veterinarsko-medicinski proizvod> može primijeniti najmanje {X} <dana><tjedana>
Animal species MRLs Target tissues 
MRL Ciljna tkiva Ostale odredbe
MANUFACTURER'S BATCH NUMBER [For terms on Batch number and Expiry date see Appendix IV on the European Medicines Agency website http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/201 4/08/WC500170559.pdf] http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/20 09/10/WC500004426.pdf] 
BROJ PROIZVODNE SERIJE [For terms on Batch number and Expiry date see Appendix IV on the European Medicines Agency website http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/20 09/10/WC500004426.pdf]
For terms on Batch number and Expiry date see Appendix IV on the European Medicines Agency website http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/201 4/08/WC500170559.pdf] http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/20 09/10/WC500004426.pdf] 
[For terms on Batch number and Expiry date see Appendix IV on the European Medicines Agency website http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/20 09/10/WC500004426.pdf]
{(Invented) name of veterinary medicinal product <strength> pharmaceutical form} {active substance(s)} 
{(Izmišljeni) naziv veterinarsko-medicinskog proizvoda <jačina>, farmaceutski oblik} {djelatna(e) tvar(i)}
<Do not store above <25 °C><30 °C>.> <Store below <25 °C><30 °C>.> <Store in a refrigerator.> <Store and transport refrigerated.>* <Store in a freezer.> <Store and transport frozen.>** <Do not <refrigerate> <or> <freeze>.> <Protect from frost.>*** <Store in the original <container><package>.> 
<Čuvati u zamrzivaču {temperaturni raspon}.> <Čuvati i prevoziti zamrznuto {temperaturni raspon}.>** <Ne <hladiti> <ili> <zamrzavati>.>
<Special warnings for each target species:> 
4.4 Posebna upozorenja za svaku od ciljnih vrsta životinja <Nema> <Cijepiti samo zdrave životinje.>
4.2 Indications for use, specifying the target species <Onset of immunity: {x weeks}> <Duration of immunity: {x years}> 
<Trajanje imunosti: {x godina}>
NAME OF THE VETERINARY MEDICINAL PRODUCT {(Invented) name of veterinary medicinal product <strength> pharmaceutical form <target species>} 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA {(Izmišljeni) naziv veterinarsko-medicinskog proizvoda, <jačina>, farmaceutski oblik <ciljne vrste životinja>}
NAME OF THE VETERINARY MEDICINAL PRODUCT {(Invented) name of veterinary medicinal product <strength> pharmaceutical form <target species>} {active substance(s)} 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA {(Izmišljeni) naziv veterinarsko-medicinskog proizvoda <jačina> farmaceutski oblik <ciljne vrste životinja>} {djelatna(e) tvar(i)}
<Keep the {container}**** tightly closed> <Keep the {container}**** in the outer carton> <in order to protect from <light> <and> <moisture>.> 
<Čuvati u originalnom<spremniku><pakovanju>.> <Držati {spremnik}**** u vanjskom kartonu.>
WITHDRAWAL PERIOD(S) <Withdrawal period(s): > 
KARENCIJA(E) <Karencija(e):>
PACKAGE LEAFLET FOR: {(Invented) name of veterinary medicinal product <strength> pharmaceutical form <target species>} 
UPUTA O VMP ZA: {(Izmišljeni) naziv veterinarsko-medicinskog proizvoda <jačina> farmaceutski oblik <ciljne vrste životinja>}
<Keep the {container}**** in the outer carton> <Keep the {container}**** tightly closed> <in order to protect from <light> <and> <moisture>.> 
<Čuvati u originalnom <spremniku><pakovanju>.> <Držati {spremnik}**** čvrsto zatvoren.> <Držati {spremnik}**** u vanjskom kartonu>
Pharmaco-logically active substance 
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNIH
<The <veterinary medicinal product><vaccine><immunological veterinary medicinal product> should be given at different sites.> 
<Veterinarsko-medicinski proizvod><cjepivo><imunološki veterinarsko-medicinski proizvod>
<This being an approval under exceptional circumstances and pursuant to Article 39(7) of Regulation (EC) No 726/2004, the MAH shall conduct, within the stated timeframe, the following measures: 
<Ovo je odobrenje pod iznimnim okolnostima, a sukladno članku 39.
<MANUFACTURER<S> OF THE BIOLOGICAL ACTIVE SUBSTANCE<S> AND> MANUFACTURER<S> RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ<I> ODGOVORAN<I> ZA PUŠTANJE SERIJE U PROMET
What Clopidogrel TAD is and what it is used for 
Što je Clopidogrel TAD i za što se koristi
Date of first authorisation: 23 September 2009 Date of latest renewal: 22 May 2014 
Datum posljednje obnove odobrenja: 22. svibnja 2014.
If you take more Clopidogrel TAD than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Ako uzmete više Clopidogrela TAD nego što ste trebali Odmah morate kontaktirati liječnika ili najbliži odjel hitne medicinske pomoći zbog povećanog rizika od krvarenja.
You should take Clopidogrel TAD for as long as your doctor continues to prescribe it. 
Clopidogrel TAD trebate uzimati sve dok Vam ga liječnik propisuje.
While you are taking Clopidogrel TAD: - You should tell your doctor if a surgery (including dental) is planned. 
Dok uzimate Clopidogrel TAD: - Obavijestite svog liječnika ako planirate kirurški zahvat (uključujući stomatološke zahvate).
Clopidogrel TAD with food and drink Clopidogrel TAD may be taken with or without food. 
Clopidogrel TAD s hranom i pićem Clopidogrel TAD se može uzimati s obrokom ili bez obroka.
An occasional use of acetylsalicylic acid (no more than 1000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor. 
Povremeno uzimanje acetilsalicilatne kiseline (ne više od 1000 mg u 24 sata) općenito ne izaziva probleme, ali o produljenom uzimanju u drugim okolnostima morate razgovarati s liječnikom.
- Your doctor may order blood tests. 
- Vaš liječnik će možda odrediti da Vam se naprave pretrage krvi.
Other medicines and Clopidogrel TAD 
Drugi lijekovi i Clopidogrel
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel TAD and acetylsalicylic acid for this condition. 
Trebalo Vam je biti rečeno da su za ovo stanje 'oralni antikoagulansi' učinkovitiji od acetilsalicilatne kiseline ili kombinirane primjene lijeka Clopidogrel TAD i acetilsalicilatne kiseline.
- If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
Ako se porežete ili ozlijedite, može trajati dulje nego obično da krvarenje prestane.
What you need to know before you take Clopidogrel TAD 
Što morate znati prije nego počnete uzimati Clopidogrel TAD
Some other medicines may influence the use of Clopidogrel TAD or vice versa. 
Neki lijekovi mogu utjecati na djelovanje Clopidogrela TAD i obratno.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu/.
Your doctor should have prescribed Clopidogrel TAD plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
Liječnik Vam treba propisati Clopidogrel TAD i acetilsalicilatnu kiselinu ako ne možete uzimati oralne antikoagulanse te nemate rizik od velikog krvarenja.
What Clopidogrel TAD looks like and contents of the pack The film-coated tablets are pink, round and slightly convex. 
Kako Clopidogrel TAD izgleda i sadržaj pakiranja Filmom obložene tablete su ružičaste, okrugle i blago konveksne.
If you forget to take a dose of Clopidogrel TAD, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time. 
Ako zaboravite uzeti jednu dozu Clopidogrela TAD, ali se toga sjetite u roku od 12 sati, odmah uzmite tabletu, a sljedeću tabletu uzmite u uobičajeno vrijeme.
Clopidogrel TAD contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. 
Clopidogrel TAD saadrži klopidogrel i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel TAD. 
Kao mjera opreza, treba prestati s dojenjem za vrijeme liječenja Clopidogrelom TAD.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel TAD in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Ako ste imali jaku bol u prsištu (nestabilna angina ili srčani udar), liječnik Vam može propisati Clopidogrel TAD u kombinaciji s acetilsalicilatnom kiselinom, tvari prisutnoj u mnogim lijekovima za ublažavanje boli i snižavanje temperature.
7 film-coated tablets: EU/1/09/555/001 14 film-coated tablets: EU/1/09/555/002 28 film-coated tablets: EU/1/09/555/003 30 film-coated tablets: EU/1/09/555/004 50 film-coated tablets: EU/1/09/555/005 56 film-coated tablets: EU/1/09/555/006 84 film-coated tablets: EU/1/09/555/007 90 film-coated tablets: EU/1/09/555/008 100 film-coated tablets: EU/1/09/555/009 
7 filmom obloženih tableta: EU/1/09/555/001 14 filmom obloženih tableta: EU/1/09/555/002 28 filmom obloženih tableta: EU/1/09/555/003 30 filmom obloženih tableta: EU/1/09/555/004 50 filmom obloženih tableta: EU/1/09/555/005 56 filmom obloženih tableta: EU/1/09/555/006 84 filmom obložene tablete: EU/1/09/555/007 90 filmom obloženih tableta: EU/1/09/555/008 100 filmom obloženih tableta: EU/1/09/555/009
What Clopidogrel TAD contains - The active substance is clopidogrel. 
Što Clopidogrel TAD sadrži - Djelatna tvar je klopidogrel.
Then, the recommended dose is one 75 mg tablet of Clopidogrel TAD per day as described above. 
Nakon toga, preporučena doza lijeka Clopidogrel TAD je jedna tableta od 75 mg dnevno, kao što je opisano iznad.
If you become pregnant while taking Clopidogrel TAD, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Ako zatrudnite za vrijeme uzimanja Clopidogrela TAD, odmah se posavjetujte s liječnikom, jer nije preporučeno uzimati klopidogrel za vrijeme trudnoće.
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel TAD per day to be taken orally with or without food, and at the same time each day. 
Preporučena doza, uključujući za bolesnike sa stanjem zvanim "fibrilacija atrija" (nepravilni otkucaji srca), je jedna tableta lijeka Clopidogrel TAD od 75 mg dnevno koja se uzima kroz usta s obrokom ili između obroka, u isto vrijeme svaki dan.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel TAD (4 tablets of 75 mg) once at the start of treatment. 
Ako ste imali jake bolove u prsištu (nestabilna angina ili srčani udar), liječnik Vam u početku liječenja može jednokratno dati 300 mg lijeka Clopidogrel TAD (4 tablete od po 75 mg).
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel TAD. 
Ako ste trudni ili sumnjate na trudnoću, obavjestite svog liječnika ili ljekarnika prije nego što uzmete Clopidogrel TAD.
This leaflet was last revised in MM/YYYY. 
Ova uputa je zadnji puta revidirana u <mjesec GGGG>.
- You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects'). 
- Također, odmah obavijestite svog liječnika ukoliko se pojavi medicinsko stanje (koje se naziva "trombotična trombocitopenična purpura" ili "TTP") sa simptomima koji uključuju vrućicu i potkožne modrice koji se mogu pojaviti kao crvene točkice, sa ili bez neobjašnjivog teškog umora, zbunjenosti i žute boje kože ili očiju (žutica) (vidjeti dio 4. 'Moguće nuspojave').
You have been prescribed Clopidogrel TAD to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack). 
Clopidogrel TAD Vam je propisan za sprječavanje stvaranja krvnih ugrušaka i smanjivanje opasnosti od ovih ozbiljnih događaja jer: - imate otvrdnuće arterija (koje se još zove ateroskleroza) te - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija. - ste imali teški oblik boli u prsištu, poznat pod nazivom “nestabilna angina” ili “infarkt miokarda” (srčani udar).
- The other ingredients are microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000 and hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000 in the film-coating. 
- Drugi sastojci su mikrokristalična celuloza, koloidni bezvodni silicijev dioksid, krospovidon (tip A), makrogol 6000 i hidrogenirano ricinusovo ulje u jezgri tablete, te poli (vinilni alkohol), titanijev dioksid (E171), crveni željezov oksid (E172), žuti željezov oksid (E172), talk i makrogol 3000 u film ovojnici tablete (vidjeti dio 2).
Driving and using machines Clopidogrel TAD is unlikely to affect your ability to drive or to use machines. 
Upravljanje vozilima i strojevima Clopidogrel TAD ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
If you stop taking Clopidogrel TAD 
Ako prestanete uzimati Clopidogrel TAD
Clopidogrel TAD is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Clopidogrel TAD uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).